Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Background CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials.